Joseph Elijah
Overview
Explore the profile of Joseph Elijah including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
7
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alaklabi S, Roy A, Zagami P, Chakraborty A, Held N, Elijah J, et al.
JCO Oncol Pract
. 2024 Oct;
:OP2400242.
PMID: 39353151
Purpose: Sacituzumab govitecan (SG) is approved for the treatment of metastatic triple-negative breast cancer (mTNBC). We report the real-world clinical effectiveness and toxicity data of SG in patients with mTNBC....
2.
Elijah J, Jain P, Holdsworth A, Baron J, Przespolewski E, Wang K, et al.
Support Care Cancer
. 2024 Aug;
32(9):622.
PMID: 39215800
Background: Trilaciclib, in comparison to placebo plus carboplatin, etoposide, ± atezolizumab (PEA), has shown significant reductions in incidence of severe neutropenia (SN) among patients with extensive-stage small cell lung cancer...
3.
Elijah J, Puzanov I, Cresanti B, Hamad L, Attwood K, Catalfamo K, et al.
J Oncol Pharm Pract
. 2024 Jul;
:10781552241264817.
PMID: 39043219
Background: Real-world safety outcomes between the two flat-dose nivolumab regimens demonstrated to be similar in a study of adjuvant nivolumab recipients for melanoma. However, this study was limited by a...
4.
Elijah J, Fitzgerald L, Phan H
Pediatr Pulmonol
. 2023 Oct;
58(12):3377-3385.
PMID: 37787417
Safety and efficacy data regarding cystic fibrosis transmembrane conductance regulator (CFTR) modulator use in the setting of pregnancy or breastfeeding remains lacking due to exclusion from key trials and lack...
5.
Elijah J, Fitzgerald L, Phan H
Pediatr Pulmonol
. 2023 Sep;
58(12):3386-3392.
PMID: 37728222
Safety and efficacy data surrounding cystic fibrosis transmembrane regulator (CFTR) modulator administration for people with CF (pwCF) and severe lung disease elect has remained unclear as a result of exclusion...
6.
Kadouh N, Elijah J, Fitzgerald L, Phan H
Pediatr Pulmonol
. 2023 Apr;
58(12):3393-3402.
PMID: 37067449
Background: Solid organ transplant (SOT) recipients with cystic fibrosis (CF) may benefit from the pulmonary and extrapulmonary benefits associated with CF transmembrane conductance regulator modulators. Nevertheless, evolution of modulator safety...
7.
Elijah J, Schepers A, Krauss J, McDevitt R
J Oncol Pharm Pract
. 2023 Feb;
29(8):1915-1920.
PMID: 36823961
Purpose: Identify risk factors for biliary toxicity in patients with colorectal liver metastases who received floxuridine (FUDR) via a surgically implanted hepatic artery infusion pump (HAIP). Describe the incidence of...
8.
Elijah J, Powell K, Smith M
J Pain Palliat Care Pharmacother
. 2022 Apr;
36(2):112-116.
PMID: 35471125
Capsaicin is a topical pain reliever that has been evaluated by randomized controlled trials (RCTs) as a potential adjunctive therapy for treating unmitigated fibromyalgia. Therefore, a review of English articles...